A blue and black background

Description automatically generatedTirzepati

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity-Journal Review

**Thursday, December 12, 2024**

**12:00-1:00pm**

**ISHV 1st Floor Conference room and**

**TEAMS**

[**Join the meeting now**](https://teams.microsoft.com/l/meetup-join/19%3ameeting_YmU0MDY1NGEtYTk0YS00OTgyLTkzZjItNDBlYTc3MzMxYzU3%40thread.v2/0?context=%7b%22Tid%22%3a%220a1a57ea-95cf-4b26-ae4d-b186c793574d%22%2c%22Oid%22%3a%22578ae073-fdf8-4061-be73-cd3fd7d1743e%22%7d)

**Meeting ID: 246 598 288 618**

**Passcode: 9GP7WJ7z**

**To claim credit,   
text PURWAB**

**to 703.260.9391**

**Or login to the CME website**

**cme.inova.org**

**Cardiology Disease Fellows Conference**

**Cardiology Disease Fellowship**

**Inova Schar Heart and Vascular**

**Accreditation:** The Inova Office of Continuing Medical Education is accredited by the Medical Society of Virginia to provide continuing medical education for physicians.

**Credit designation:** The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 1.0 credit in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

**Target audience:** Members of the medical staff, cardiology practitioners, fellows

**Learning objectives:**

* Investigate the impact of Tirzepatide on cardiovascular outcomes in patients with HFpEF & obesity
* Identify methodological weaknesses and potential biases in the trial
* Evaluate the applicability of the SUMMIT trial's findings to broader patient populations

**Rhea Green, MD**

**Cardiovascular Fellow**

**Inova.org**